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Abstract
Objective. Urotensin II is a potent vasoactive peptide that has been implicated in the pathophysiology of many diseases. There is
no study reporting the role and level of this peptide in recipients of kidney transplant. So we aimed to study the plasma levels of
urotensin II in this group of patients.
Methods. Plasma urotensin II levels were analyzed in 110 subjects, who were divided into three groups: group 1 (35 kidney
transplant recipients), group 2 (36 patients with chronic kidney disease), and group 3 (39 healthy controls).
Results. Analysis of logarithmic transformation of urotensin II, i.e. log (urotensin II  1000) levels, with a one-way analysis of
variance yielded a P value of 0.001. Post-hoc analysis showed signiﬁcantly higher log (urotensin II  1000) levels in group 1 than
groups 2 and 3 (P = 0.001 and 0.017, respectively). One of the important features of the subjects of this group was that they
were taking immunosuppressive drugs because of renal transplantation.
Conclusions. High urotensin II levels in recipients of kidney transplants could be drug-related (immunosuppressive drugs) and
may be of practical importance that may be used to improve the long-term outcome of the patients.
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Introduction
UrotensinII(UII)isapotent11-aminoacidvasoactive
peptide that produces vasodilatation and inotropic
effects in addition to its powerful vasoconstrictive
effect. UII acts by binding to a G(q/11) protein-
coupledurotensinIIreceptor(UTR)(1).Recentstud-
ies have shown increased expression of UII and its
receptors in animals and patients with hypertension,
heart failure, atherosclerosis, and diabetic nephro-
pathy (1–4). Thus, UII has been implicated in the
pathophysiology of the above-mentioned disorders.
The kidney plays a major role in UII production,
which may contribute to its hemodynamic effects (5).
UII can also be synthesized in non-renal tissue, such
as the heart (6). Some researchers have shown that
UII may play a cardioprotective role in patients with
ischemic heart disease and chronic renal failure (7,8).
Furthermore,severalstudieshaveshownincreasedUII
levels in patients with chronic kidney disease (CKD)
(1,2,9,10). Kidney transplantation is an important
treatment model for CKD, and it is being increa-
singly employed worldwide (11,12). To our know-
ledge, no studies have been reported regarding
Correspondence: Dr Mehmet Hursitoglu, Internal Medicine Department, VakIf Gureba Training & Research Hospital, 34100 Fatih, Istanbul, Turkey.
Fax: +90 212 5722258. E-mail: hursitoglum@yahoo.com
(Received 4 September 2011; accepted 19 September 2011)
ISSN 0300-9734 print/ISSN 2000-1967 online   2012 Informa Healthcare
DOI: 10.3109/03009734.2011.626541UII levels in patients who have undergone a kidney
transplantion.Thus,thepurposeofthispilotstudywas
to investigate and compare UII levels among kidney
transplant recipients, CKD patients, and normal
subjects.
Materials and methods
Thisstudywasapprovedbyourlocalethicsboard,and
written informed consent was obtained from all parti-
cipants. Altogether 110 subjects were enrolled, and
they were divided into three groups (Table I). The
exclusion criteria were: age <18 years; presence of
ischemic heart disease, chronic liver disease, or malig-
nancy; or an inability to provide written consent. The
inclusion criteria were as follows: For group 1 (tx)
patients: those who had a kidney transplant for more
than 4 months and no signs and/or symptoms of any
acute or chronic infection or rejection. For group
2 (CKD) patients: those with stages 4 and 5 CKD
(13), and in whom dialysis therapy had not been
initiated. For group 3: healthy control subjects with
normalrenalfunctionandnoobvious acute orchronic
disease.
After obtaining demographic data of the partici-
pants, a thorough clinical evaluation and physical
examination (including measurements of weight,
height, and blood pressure) were performed.
After an overnight fast, blood samples (without anti-
coagulant) for urea and creatinine determination and
another one for urotensin II assay (details below)
were drawn from the participants. The above-
mentioned tests were performed at Ahenk Laboratory
(Istanbul, Turkey). Glomerular ﬁltration rate (GFR)
was calculated according to the Cockcroft–Gault
formula (GFR = [140–age]  weight (kg) / [serum
creatinine  72]  0.85, if female) (14).
UII assay
Urotensin II (human) was measured by an enzyme-
linked immunoassay (EIA) method (15). A speciﬁc
and sensitive EIA kit was used for this assay (Phoenix
Pharmaceutical Inc., California, USA). The intra-
and inter-assay coefﬁcients of variations were <15%
and <5%, respectively. The minimum detectable con-
centration was 0.06 ng/mL. There was no cross-reac-
tivity with endothelin-1, angiotensin II, PAMP-20, I-
ANP-28, bradykinin, and neurotensin, but there was
<15.7% cross-reactivity with UII-related peptides.
Blood samples were collected into Lavender Vacutai-
ner tubes, which contained EDTA and aprotinin
(0.6 TIU/mL of blood). Then, plasma was stored
at –70C until the day of the assay (not exceeding
20 days). Plasma extraction and assay of UII was
performed according to the instructions of the man-
ufacturer. The standard peptide was solved in the
assay buffer that contained NaH2PO4,N a 2HPO4,
NaCl, EDTA, bovine serum albumin (BSA), and
sodium azide. A standard curve was obtained from
the known concentrations of standard peptide on the
log scale (x-axis), and its corresponding optic density
(OD) reading (carried out at 450 nm) on the linear
scale (y-axis). There was negligible difference as
regards optical properties at the actual wavelength
between the medium for standards and the plasma
extract. The concentration of UII in a sample was
determined by locating its OD on the y-axis, then
drawing a horizontal line to intersect with the stan-
dard curve. From this point, a vertical line was drawn
Table I. Characteristics of the participants.
Group 1 Group 2 Group 3 P value
n 35/110 36/110 39/110 -
Age (years) 37.4 ± 13.8 36.8 ± 6.8 38.3 ± 5.6 NS
Sex (F/M) (n) 12/23 14/22 18/21 NS
Creatinine (RI 0.60–1.10 mg/dL) 1.10 ± 0.20 5.98 ± 1.52 0.75 ± 0.23 0.001
a,N S
b, 0.000
c
CCBs
d 24/35 (68.6%) 21/36 (58.3%) 0/39 (0.0%) NS
a
ACE inhibitors or ARBs
d 10/35 (28.6%) 14/36 (38.9%) 0/39 (0.0%) NS
a
UII (ng/mL) 0.66 (0.16–188)
e 0.48 (0.06–1.14)
e 0.59 (0.06–1.85)
e 0.017
f
aComparing group 1 with group 2.
bComparing group 1 with group 3.
cComparing group 2 with group 3.
dAlone or in combination with other antihypertensive drugs.
eMedian (min–max).
fKruskal–Wallis test.
RI = reference interval; NS = not signiﬁcant; CCBs = calcium channel blockers; ACE = angiotensin-converting enzyme; ARBs = angiotensin
receptor blockers; UII = plasma urotensin II level.
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the sample was calculated. If necessary, samples were
diluted prior to the assay, and then the measured
concentration was multiplied by their respective dilu-
tion factors.
Statistical analysis
Normallydistributeddataareexpressedasmean±SE.
When data are not normally distributed, the median,
maximum, and minimum values are also given. The
normally distributed data were compared by one-
way ANOVA, whereas the not-normally distribu-
ted data were compared using Kruskal–Wallis test.
ANOVA was followed by Tukey’s HSD test,
wherever applicable. Univariate two-way ANOVA
and Mann–Whitney U test were used to analyze the
differences in UII levels between males and females
subgroups. A two-sided P < 0.05 was considered
signiﬁcant.
Results
No differences were observed in age and gender
between the groups, but the creatinine levels in group
2 differed from those in groups 1 and 3 (P = 0.001
and < 0.0001, respectively) (Table I). The GFRs of
groups 1, 2, and 3 were 81.29 ± 17.92, 16.74 ± 4.32,
and 198.36 ± 100.03 mL/min, respectively. No his-
tory of drug use, diabetes mellitus (DM), hyperten-
sion (HT), or other co-morbidities were reported in
group 3. No signiﬁcant difference was observed in the
rate of use of calcium channel blockers (CCBs),
angiotensin-converting enzyme (ACE) inhibitors, or
angiotensin receptor blockers (ARBs) (alone or in
combination with other antihypertensive agents)
between the patients in groups 1 and 2 (P > 0.05)
(Table I). On the other hand, all patients in group
1 (tx) were on immunosuppressive drug treatment,
i.e. calcineurin inhibitor (28 patients on cyclosporine
and 7 patients on tacrolimus), azathioprine
(7 patients), or mycophenolate (28 patients), and
prednisolone (30 patients). Calcineurin inhibitors
were adjusted according to blood levels (cyclosporine
and tacrolimus daily doses were 289.57 ± 129.43
and 15.57 ± 1.90 mg, respectively) and daily doses
of azathioprine, mycophenolate, and prednisolone
were 1–3 mg/kg, 2 g, and 5–35 mg, respectively.
Duration of transplantation (group 1) was 24.0
(4.5–144.0) months. No difference in the frequencies
of DM or HT was observed between the patients in
groups 1 and 2 (3% versus 3%, P = 0.175; and 37%
versus 39%, P = 0.219, respectively), but the combi-
nation of DM and HT was lower in group 1 than in
group 2 (3% versus 42%, P < 0.001).
Themedian(min–max)valuesofUIIwereasgiven
inTableI.WhentheseUIIconcentrationswerecom-
pared by Kruskal–Wallis test, the total P value was
0.017. When logarithmic transformation was exe-
cuted regarding UII (ng/mL) levels, the log (UII 
1000) levels showed a normal distribution (15,16).
These log (UII  1000) levels were then used for
further analyses. When the log (UII  1000) levels
b e t w e e nt h eg r o u p sw e r ec o m p a r e db yo n e -
way analysis of variance (ANOVA), the P value was
0.001 (Table II). Tukey’s HSD post-hoc analysis
revealedasigniﬁcantdifferencebetweentheUIIlevels
in group 1 and those in groups 2 and 3 (P = 0.001 and
0.017, respectively), but no signiﬁcant difference was
observed between the UII levels in groups 2 and
3( P = 0.541).
There was no correlation between age, creatinine
levels, GFR, co-morbidities (DM and HT), antihy-
pertensive drug use, or log (UII  1000) levels among
the three groups. In group 1, there was also no
correlation between log (UII  1000) levels and
transplantation duration or immunosuppressive
drug doses.
Table II. Comparison of log (UII  1000) levels between males and females.
Groups Log (UII  1000) levels (total)
a Gender No. of cases
Log (UII  1000) levels
Mean ± SE
1 3.0035 ± 0.60478 Male 23 3.0686 ± 0.67444
Female 12 2.8787 ± 0.44153
2 2.6403 ± 0.29595 Male 22 2.7468 ± 0.22989
Female 14 2.4730 ± 0.31798
3 2.7400 ± 0.24080 Male 21 2.7607 ± 0.27365
Female 18 2.7158 ± 0.20089
aOne-way analysis of variance (ANOVA) test’s P value was 0.001 (see text).
UII = plasma urotensin II level (ng/mL); SE = standard error of the mean.
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(UII  1000) levels than females (P = 0.039 on uni-
variate two-way ANOVA) (Table II and Figure 1).
Further analysis by Mann–Whitney U test, however,
showed that only group 2 males log (UII  1000)
levels were signiﬁcantly higher than females, while
log (UII  1000) levels of males in groups 1 and 3
were not (2.77 [2.27–3.06] versus 2.56 [1.74–2.82],
2.82 [2.26–5.27] versus 2.85[2.19–4.04], and 2.78
[1.78–3.27] versus 2.70 [2.39–3.04]; median (min-
max)values;P=0.009,0.578,and0.266,respectively).
Discussion
Some investigators implicate UII in the pathophy-
siology of many diseases including CKD. Previous
studies have shown an increase in the UII levels in
patients with CKD, including those undergoing
hemodialysis (HD) (1).
Mosenkis et al. (17) compared the UII levels in
three patient groups: patients on HD (group 1),
patients with CKD not on HD (group 2), and subjects
with normal renal function (group 3). In contrast to
the results of previous studies, they found that the
mean plasma UII levels (pg/mL) were highest in
group 3, low in group 1, and lowest in group
2 (22445 ± 652, 16351 ± 641, and 13773 ± 652,
respectively; P < 0.0001). The very low UII level in
group 2 was attributed mostly to reduced production
and simultaneous increased clearance of UII by dis-
eased kidneys in comparison to the patients on HD.
In our study, the plasma UII levels tended to
be higher in control subjects (group 3) than in
patients with CKD but not on HD treatment (group
2) (Table II), but the results were not statistically
signiﬁcant; post-hoc analysis showed P > 0.05. The UII
measurements in our study were made by enzyme-
linked immunoassay, whereas the above study used
radioimmunoassay. This difference in methodology
may partly explain the difference in the results of
these studies (1).
In Mosenkis’s study 60% of the subjects in the
control group were hypertensive, and 23% were dia-
betic; while in our study the control group subjects
were neither hypertensive nor diabetic (we aimed in
our study to compare UII concentrations observed in
normal physiological conditions with those observed
in diseased conditions; therefore, subjects in our
control group were selected from completely healthy
subjects). This difference in the rate of hypertensive
and diabetic subjects between the control groups of
the two studies may also explain the differences in the
results (1,3,18–20).
Another feature of Mosenkis’ study is the presence
of African-Americans in the study population (17).
African-Americans have a high prevalence of insulin
resistance but paradoxically a low prevalence of met-
abolic syndrome (21). These ethnicity and race dif-
ferences between the two study groups may also
explain the differences in the results of UII between
the two studies (10,21).
Interestingly, the plasma UII level was signiﬁcantly
higher in the tx (group 1) patients than in the other
two groups in our study (Table II and Figure 1).
Kidneys have a major role in UII production (5). Still
this increased plasma level could not be explained
solely by the transplanted kidney, because the plasma
level is higher than that of the healthy controls who
had two normal functioning kidneys. The tx group
was on immunosuppressive medications (mostly cal-
cineurin inhibitor, azathioprine or mycophenolate,
and prednisolone) (11). The calcineurin inhibitors
cyclosporine (CsA) and tacrolimus can cause HT
and induce acute and chronic nephrotoxicity by dif-
ferent mechanisms such as vasoconstriction (through
the release of different vasoactive substances) and
tubulointerstitial ﬁbrosis (22–25). Cyclosporine infu-
sion can lead to proximal tubular damage through an
increase in intracellular Ca
2+, which is completely
prevented by the calcium channel blocker nifedipine
(25). Up-regulation of UII and its receptor can also
cause renal ﬁbrosis and dysfunction (4). Moreover,
UII has a vasoconstrictive effect. Activation of UTR
by UII increases phosphoinositide (PI) turn-over with
an increase in intracellular Ca
2+. The PI turnover
and vasoconstrictive effect of UII are inhibited by
phospholipase C inhibition with 2-nitro-4-carboxy-
phenyl-N (1,26). The calcium channel blockers
verapamil, nifedipine, and diltiazem can also inhibit
the vasoconstrictive effect of UII (26).
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Figure 1. Comparison of log (UII  1000) levels between the
groups. EMM = estimated marginal means; UII = urotensin II
(ng/mL).
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of patients with a transplanted kidney and on the CsA
nephrotoxicity rate, even at similar daily doses. This
has been attributed to differences in sex hormones
between males and females (27,28). The difference in
males’ and females’ log (UII  1000) levels in group 2
of our study (Table II and Figure 1) may explain this
gender difference in the rate of graft survival. The
similarity in the effect of UII and the side-effects of
calcineurin inhibitors, which can be partially pre-
vented by calcium channel blockers, shows that a
relationship may exist between calcineurin inhibi-
tors and the elevated UII levels in our tx patients.
None of our group 1 patients was on calcineurin
inhibitor-sparing regimens (as we mentioned before,
we tried to include somewhat stable and non-com-
plicated patients in this group), so we did not have the
chance to see UII levels in patients not taking calci-
neurin inhibitors. Comparing log (UII  1000) levels
(med [min–max]) of cyclosporine with tacrolimus-
taking groups yielded no signiﬁcant difference (2.82
[2.19–5.27] versus 2.89 [2.52–3.76], respectively;
P = 0.88). But we should mention that the
tacrolimus-taking group (n = 7) was small.
There is an international effort to standardize and
improve the management of this important popula-
tion of patients (11). Measuring plasma UII levels at
different stages, including nephrotoxicity, rejection,
and other complication states, with different immu-
nosuppressive drug dosing and regimens may help
elucidate the role of UII in the above-mentioned
medical conditions and may lead to the generation
of new treatment models that modulate the level and
effect of UII.
Conclusion
The high UII level in tx patients in comparison with
healthy controls could be attributed to the use of
mandatory immunosuppressive drugs. Further stud-
ies are needed to ascertain the beneﬁcial and/or
harmful aspects of elevated UII levels to improve
management strategies for kidney recipients.
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